Mirum Pharmaceuticals Provides Development Program Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiative
- Oil inches higher, stays near six-month highs on Saudi attacks
Citi Reiterates Buy Rating on Mirum (MIRM), PT $34, 'Volixibat ICP Trial Discontinued, PSC and PBC Readouts Remain On Track'
November 29, 2022 9:05 AM ESTCiti analyst David Lebowitz reiterated a Buy rating and $34.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM)
The analyst comments "Today, Mirum announced the discontinuation of Phase IIb OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to challenges in... More



